Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adaptive Design

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    73 result(s) found for: Adaptive Design. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-000585-38 Sponsor Protocol Number: SQ411218 Start Date*: 2019-08-20
    Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust
    Full Title: Chronic Endometritis and Recurrent Miscarriage - The CERM trial
    Medical condition: Chronic Endometritis and Recurrent Miscarriage
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-003405-98 Sponsor Protocol Number: dexFEMv2 Start Date*: 2012-12-03
    Sponsor Name:ACCORD University of Edinburgh [...]
    1. ACCORD University of Edinburgh
    2. ACCORD, NHS Lothian
    Full Title: Developmental Clinical Studies - Reversing endometrial glucocorticoid deficiency in heavy menstrual bleeding
    Medical condition: Endometrial glucocorticoid deficiency in Heavy Menstrual Bleeding
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10027313 Menorrhagia PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003122-88 Sponsor Protocol Number: SELK2-00005 Start Date*: 2019-01-21
    Sponsor Name:Tetherex Pharmaceuticals Corporation
    Full Title: A Phase 2, Randomized, Active Comparator-Controlled, Open-Label, Adaptive Design Study to Assess the Safety and Efficacy of Intravenously-Administered SelK2 in Patients Undergoing Total Knee Arthro...
    Medical condition: Venous thromboembolism occurring in patients undergoing total knee replacement arthroplasty
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023155-28 Sponsor Protocol Number: AGO/2010/006 Start Date*: 2011-02-14
    Sponsor Name:Ghent University Hospital
    Full Title: Dexmedetomidine pharmacokinetics-pharmacodynamics in mechanically ventilated neonates with single-organ respiratory failure (NEODEX)
    Medical condition: Patients admitted to the neonatal intensive care unit with single-organ respiratory failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10053349 Pharmacokinetic study LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000720-98 Sponsor Protocol Number: RXC004/0001 Start Date*: 2017-06-19
    Sponsor Name:Redx Pharma plc
    Full Title: A Modular, Multi-Arm, Phase 1/2a, Adaptive Design Study To Evaluate The Safety And Tolerability Of RXC004, Alone And In Combination With Anti-Cancer Treatments, In Patients With Advanced Malignancies
    Medical condition: Patients with Advanced Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002700-14 Sponsor Protocol Number: NA-0113-200-EU Start Date*: 2018-12-14
    Sponsor Name:Navad Life Sciences Pte Ltd
    Full Title: Single-center, open-label, adaptive design study to evaluate the influence on hormonal and ovarian function and vaginal bleeding pattern of different dosages of levonorgestrel administered once dai...
    Medical condition: Investigation of ovulation inhibition for indication of contraception
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10073728 Hormonal contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001429-33 Sponsor Protocol Number: IM140-103 Start Date*: 2014-11-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP)
    Medical condition: Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002299-11 Sponsor Protocol Number: SD-COVID19-01 Start Date*: 2020-09-17
    Sponsor Name:SigmaDrugs Research Ltd.
    Full Title: A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-...
    Medical condition: SARS-CoV-2 infected patients
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000436-28 Sponsor Protocol Number: Z102-008 Start Date*: 2011-12-07
    Sponsor Name:Zalicus, Inc.
    Full Title: A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOI...
    Medical condition: Treatment of patients with moderate to severe rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005008-41 Sponsor Protocol Number: 2007033 Start Date*: Information not available in EudraCT
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-controlled, 58-day, Dose-ranging Study of ATI-7505 in Patients with Postprandial Distress Syndrome
    Medical condition: Postprandial Distress Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064536 Functional dyspepsia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006134-17 Sponsor Protocol Number: IPM3002 Start Date*: 2012-07-30
    Sponsor Name:ZIOPHARM Oncology, Inc.
    Full Title: A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etopo...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) PL (Completed) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007515-33 Sponsor Protocol Number: Mel-Swe-01 Start Date*: 2009-08-13
    Sponsor Name:SentoClone AB
    Full Title: A multi-centre, two-arm, randomized, open, phase II study of adaptive design investigating SentoClone® compared to reference treatment in advanced malignant melanoma
    Medical condition: Surgically incurable stage III or IV malignant melanoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025670 Malignant melanoma stage III PT
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004590-90 Sponsor Protocol Number: 3415A-001 Start Date*: 2012-02-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium ...
    Medical condition: recurrence of Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) BE (Completed) DK (Completed) PT (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003634-93 Sponsor Protocol Number: NLG2107 Start Date*: 2018-02-28
    Sponsor Name:NewLink Genetics Corporation
    Full Title: A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo plus Pembrolizumab or Nivolumab in Adult Patients with Unresectable Stage III or Stage IV Malignant Mel...
    Medical condition: Adult Patients with Unresectable Stage III or Stage IV Malignant Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000037-13 Sponsor Protocol Number: PTK0796-AP-17202 Start Date*: 2018-09-04
    Sponsor Name:Paratek Pharma, LLC, a wholly-owned subsidiary of Paratek Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults with Acute Pyelonephritis
    Medical condition: Acute Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10001032 Acute pyelonephritis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-002721-29 Sponsor Protocol Number: 08486 Start Date*: 2018-12-24
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy
    Medical condition: Mitochondrial Myopathy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-000438-21 Sponsor Protocol Number: 750201.01.035 Start Date*: 2012-10-17
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, double-blind, placebo-controlled, randomized phase III study to prove the efficacy, safety and tolerability of Silexan (WS®1265) in patients with mixed anxiety and depressive disorder...
    Medical condition: mixed anxiety and depressive disorder (ICD-10, F41.2)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10027741 Mixed anxiety & depressive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000643-27 Sponsor Protocol Number: MK-1029-012-00 Start Date*: 2012-12-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects with Persistent Asthma
    Medical condition: Adult subjects 18 to 75 years of age with persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000445-39 Sponsor Protocol Number: ACI-24-1801 Start Date*: 2018-06-19
    Sponsor Name:AC Immune SA
    Full Title: A Phase II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study to Assess the Safety, Tolerability, Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild ...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-002340-14 Sponsor Protocol Number: REMAP-CAP Start Date*: 2015-09-16
    Sponsor Name:University Medical Center Utrecht
    Full Title: Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19)
    Medical condition: Severe Community Acquired Pneumonia COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Ongoing) BE (Trial now transitioned) DE (Ongoing) HR (Ongoing) ES (Temporarily Halted) FR (Trial now transitioned) FI (Ongoing) IT (Ongoing) CZ (Trial now transitioned) SI (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA